Tau Therapeutics is developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type calcium channel blockade with Tau’s drugs is intended to arrest tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.
Tau’s first product candidate, mibefradil, has been used extensively in humans and its safety profile is well known. Mibefradil is now entering clinical trials for brain cancer with support from the National Cancer Institute.
Tau Therapeutics is a privately held company based in Charlottesville, VA.